Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Beigene

10/21/2021 | 05:41pm EST


ę MT Newswires 2021
All news about BEIGENE, LTD.
12/03China's Medical Products Regulator Approves BeiGene's Sylvant for Multicentric Castlema..
MT
12/03Beigene Grants Share Options to Five Employees
MT
12/03China Includes Three Beigene Drugs to New National Reimbursement Drug List
MT
12/02BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT« (Siltuximab for Injection) i..
BU
12/02BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tis..
BU
12/02BeiGene Announces Inclusion in the China National Reimbursement Drug List of Tislelizum..
CI
12/02BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
BU
12/02BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
CI
11/30BeiGene to Raise $3.5 Billion in Shanghai IPO; Shares Jump 3%
MT
11/30BeiGene Prices Shanghai Stock Exchange IPO
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 184 M - -
Net income 2021 -1 240 M - -
Net cash 2021 3 103 M - -
P/E ratio 2021 -23,7x
Yield 2021 -
Capitalization 32 284 M 32 284 M -
EV / Sales 2021 24,7x
EV / Sales 2022 21,6x
Nbr of Employees 7 600
Free-Float 67,7%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 314,14 $
Average target price 435,26 $
Spread / Average Target 38,6%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Lai Wang Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.36.22%32 284
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819